Founder and Managing Director
Gregg applies more than 20 years of experience in the life science and technology industries, ranging from venture-backed start-ups to publicly traded companies. He previously served as CFO of two public and three privately held companies, during which time he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development and manufacturing functions. Gregg’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device, and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg holds a BA from Middlebury College, JD from the University of Pittsburgh School of Law and MBA from Carnegie Mellon University.
Founder and Managing Director
Daniel brings more than 30 years of experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, he has participated in seven initial public offerings. Over the course of his career, he has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.
Steve has more than 30 years of experience in life sciences and healthcare, including founding two start-ups and working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies. He previously served as CFO of two public companies and as CFO, COO, CEO or Director of eight privately held companies, in addition to his consulting clients. He has managed finance, accounting, corporate communications, human resources, information technology, facilities, business development, and manufacturing functions. Steve participated in the successful reorganization of Cambridge Biotech from Chapter 11 bankruptcy protection into Aquila BioPharmaceuticals, led the effort to take RXi public, and has extensive experience in international fundraising and corporate structuring. He was formerly Chairman of Cognoptix and is on the Board of Phytera, Inc. Steve’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. He holds a BS from the University of Massachusetts and MBA from Babson College.
As President, Chris oversees Danforth’s internal operations team as well as the growth and expansion of the company and its service offerings. Prior to joining Danforth, Chris spent nearly 15 years in senior leadership positions at Vistaprint, where he was instrumental to the company’s growth from start-up operations to achieving over $1 billion in revenue. Among his responsibilities, he led the strategic direction and roll-out of new customer support services, as well as the infrastructure design and personnel needs required for their operation. He most recently served as the company’s Senior Vice President of Technology and Transformation, overseeing all aspects of software development and people operations. Prior to joining Vistaprint, Chris spent seven years as a senior technical consultant at Envisa and Accenture. He holds a BS in Management Information Systems from Babson College.
Managing Director, Mid Atlantic Region
Rob is an accomplished C-level executive with more than 20 years of experience leading life science and medical device companies, both private and public, ranging from early-stage development to commercial operations. Prior to joining Danforth, he served as CFO to multiple companies, including Motif Bio (NASDAQ/AIM: MTFB), Tyme Technologies, Inc. (NASDAQ: TYME), BeyondSpring Pharmaceuticals, Inc. (NASDAQ: BYSI) and NeoStem, Inc. – now Caladrius Biosciences, Inc. (NASDAQ: CLBS). He previously spent nearly 20 years in investment banking at Lehman Brothers and Legg Mason. Rob is experienced in all stages of the corporate lifecycle, including start-up operations, high growth, turnarounds and exit strategies. His expertise includes building organizations, public and private financings, M&A, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interactions with boards, venture capitalists, shareholders and Wall Street. Rob holds an AB from Princeton University and MBA from The Wharton School, University of Pennsylvania.
Managing Director and Practice Lead, Risk Management Consulting Services
Stacey joined Danforth in 2019 to lead the firm’s Risk Management Consulting Services Practice, bringing more than 25 years of experience in advisory and implementation services related to Sarbanes Oxley (SOX) Readiness/Compliance, Internal Controls, Process Design, Information Technology (design, implementation and control assurance), Corporate Governance and Enterprise Risk Management for life science companies. A former Deloitte partner from 1998-2014, she is recognized for her global experience developing financial policies, processes and oversight tools; using a simple, efficient and effective approach. Previously, Stacey had direct experience working as a regional controller, systems implementation project leader (including implementing/configuring Lawson, Oracle, Workday and SAP) and director of internal audit/compliance. Stacey holds a BS in Accounting from Drexel University and is a CPA in the states of Massachusetts and Arizona.
Managing Director, New York Metro Region
Heather joined Danforth in 2015 with nearly 30 years of experience spanning private and public, start-up and later-stage organizations in the medical equipment and pharmaceutical industries. As an operational CFO, she has implemented strategic plans into corporate operations across functional areas including human resources, finance and accounting, research and development, manufacturing, quality, sales and marketing departments, while maintaining exceptional financial control and transparency to all stakeholders. Her Danforth clients have included Homology Medicines, Immuneering, Kallyope, Opsonix, Pear Therapeutics and SpringWorks Therapeutics, among others. Prior to joining Danforth, she held finance leadership roles for Cytonome and AutoImmune. Heather earned a BA from the University of California, San Diego, and MBA from the University of Michigan Graduate School of Business.
Managing Director, New England
Jon joined Danforth in 2018 with 25 years of experience in financial and executive management at emerging and growth-stage life science companies and in investment banking. As a former CFO, he raised more than $300 million of equity and debt in public and private securities offerings, including a $110 million IPO at Altus Pharmaceuticals, and led strategic and business development transactions including the successful sale of Xcellerex to GE Healthcare. He most recently served as CFO of Histogenics Corporation, a publicly-held cell therapy company developing products for the orthopedics market. He additionally held the roles of CFO for Metamark Genetics, Inc. and CFO and Treasurer of Repligen Corporation. Previously, Jon was an investment banker for 10 years, during which time he originated and executed on numerous corporate financings and merger and acquisition transactions at SG Cowen and Salomon Brothers Inc. He received a BS in Business Administration and Finance from Boston University and an MBA in Finance from New York University Stern School of Business.
Managing Director, Texas
Mariam is a seasoned financial executive with more than 25 years of in-house and consulting experience. Prior to joining Danforth, she served as CFO, Secretary and Treasurer of Cerecor, Inc. (NASDAQ: CERC), leading the company through its IPO, multiple corporate acquisitions and licensing arrangements. She previously founded and led a consulting firm, guiding life science clients at various stages of operation and often serving in outsourced CFO and CBO roles. She additionally served as CFO of Sucampo Pharmaceuticals (NASDAQ: SCMP), where she led the company’s private crossover round and IPO. Mariam’s wide-ranging expertise includes strategic planning, corporate acquisitions, licensing, investor relations, internal controls for public and private companies, SOX compliance and oversight of human resources and information technology. She also has significant SEC reporting, tax, acquisition, technical accounting, budgeting, treasury, operations and project management experience. Mariam is a member of the American Institute of Certified Public Accounts (AICPA) and the Texas Society of Certified Public Accountants (TSCPA). She earned an MA in Taxation from Old Dominion University and a BA in Accounting from Texas Tech University.
Managing Director, West Region
Jeff joined Danforth in 2017 to lead the firm’s growth in the western US, based in Colorado. He brings more than 25 years of experience to the role, both as a former investment banker and a strategic financial executive with expertise in operations and transactions for private and public companies. He previously held senior leadership positions for Great Basin Scientific, GlobeImmune, AlgoRx Pharmaceuticals and Antigenics, and later formed a successful life sciences financial advisory practice. He has raised more than $500 million for start-up companies and also led multiple liquidity events. Jeff began his career at Coopers & Lybrand and UBS Investment Bank, and holds a BS in Accounting from Case Western Reserve University.
Managing Director and Practice Lead, Digital Health
Bill joined Danforth in 2016 to build and lead the Healthcare Technology/Digital Health platform. As a passionate and seasoned CFO with over 25 years of strategic financial and operational management experience, Bill has successfully navigated several companies through rapid growth. His broad experience includes executive leadership with high growth and commercially driven healthcare technology and life science companies such as Humedica (sold to UnitedHealth), NaviNet (sold to Lumeris), SynapDx and ZappRx. Bill has led several successful M&A initiatives, including the highly strategic sale of Humedica to UnitedHealth in 2013. He is recognized for scaling, managing and leading rapidly growing health technology companies and has a successful history of financing via public/private equity transactions, raising more than $300 million. Bill holds a BA from Villanova University and MBA from the University of Massachusetts.
Managing Director and Practice Lead, Clinical Outsourcing Management
Heather joined Danforth in 2019 to lead the firm’s Clinical Outsourcing Management practice, bringing nearly 20 years of experience in drug discovery and development in the pharmaceutical industry. She previously served as Associate Director, Head of Operations & External Services Management at EMD Serono, a US subsidiary of Merck KGaA. There she built and managed a clinical bioanalysis outsourcing group, and led a global team responsible for delivering clinical pharmacokinetic data from global vendors in the US, Europe and China to support the entire clinical pipeline at Merck KGaA. Before EMD Serono, Heather served in several positions at Pfizer, including Biotherapeutic Sourcing Lead and Head of Biotherapeutic Discovery Group. She has a broad spectrum of experience in biotherapeutic discovery technologies, bioanalysis, vendor management, research operations and clinical outsourcing. Heather holds a BS in Chemistry and an MBA from the University of Massachusetts, Lowell, and a PhD in Biochemistry from Tufts University of Medicine, Boston.
Managing Director, New England
Lance has more than 30 years of experience as a life science CFO and senior executive. He brings extensive knowledge in IPO preparations and post-public SEC compliance, as well as financial operations and strategy at all phases of the corporate life cycle, including capital financing, corporate governance and investor and banking relations. He has served over 20 life science companies as interim CFO or C-level advisor, including Pieris Pharmaceuticals, Proteostasis Therapeutics, Stoke Therapeutics, Centrexion Therapeutics and NextCure. Prior to joining Danforth, Lance spent 12 years at PricewaterhouseCoopers, where he was an integral member of the Transaction Advisory Services Global Capital Markets Group in London, England. He is a CPA and holds a BS in Accountancy from Bentley College.